Deletion of TIM-3, LAG-3, and 2B4 genes by CRISPR-Cas9 led to superior functionality and resistance to exhaustion of transgenic TCR NY-ESO-1-specific T cells in preclinical myeloma models. The gene discussed is CD244; the disease is plasma cell myeloma.